TGEN Tecogen Inc

Targeted Genetics Invites You to Join its Fourth Quarter and Year-End Earnings Call on the Web SEATTLE, Feb. 26 /PRNewswire-FirstCall/ -- Targeted Genetics Corporation invites you to listen to its investor and analyst conference call, which will be held in conjunction with the release of the Company's Fourth Quarter and Year-End financial results. The call will be broadcast live over the Internet on Monday, March 1, 2004, at 10:30 AM EST. What: Targeted Genetics Corporation Year-End 2003 Financial Results When: March 1, 2004, 10:30 AM EST Where: http://www.targetedgenetics.com/ If you are unable to participate during the live webcast, the call will be archived for 30 days at http://www.targetedgenetics.com/. The replay also will be available for 30 days by dialing 800-207-7077 (domestic) or 913-383-5767 (international) and using PIN #4074. Targeted Genetics develops gene-based products for preventing and treating acquired and inherited diseases. The Company has two clinical product development programs, targeting cystic fibrosis and AIDS prophylaxis and expects to initiate clinical testing of its arthritis product candidate in the first quarter of 2004. The Company also has a promising pipeline of product candidates focused on hemophilia and cancer and a broad platform of gene delivery technologies, as well as a promising body of technology for cellular therapy under development by its subsidiary company, CellExSys. For more information about the Company visit its website at http://www.targetedgenetics.com/. NOTE: This release contains forward-looking statements regarding our product pipeline and clinical trials. These statements involve current expectations, forecasts of future events and other statements that are not historical facts. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of forward-looking statements. Actual results could differ materially from expectations for a number of reasons, including our failure to make progress with our clinical trials, our failure to obtain positive results from our preclinical programs, our failure to obtain regulatory approval and the other risks described in the section entitled "Factors Affecting Our Operating Results, Our Business and Our Stock Price" in our report on Form 10-Q for the quarter ended September 30, 2003. You should not rely unduly on these forward-looking statements, which apply only as of the date of this release. We undertake no duty to publicly announceor report revisions to these statements as new information becomes available that may change our expectations. DATASOURCE: Targeted Genetics Corporation CONTACT: Courtney Self of Targeted Genetics Corporation, +1-206-521-7392 Web site: http://www.targetedgenetics.com/

Copyright